The Definitive Infrastructure for Modern Drug Development
Paradigm Health has launched an AI‑powered clinical research platform that operates across a national network of more than 800 community and academic sites in the United States, Japan and Israel. The platform embeds trial design, patient identification and data capture directly into real‑world care workflows, promising faster enrollment, higher‑quality data and lower operational costs. By linking electronic health records to eCRFs through FHIR and HL7 standards, the solution automates source data capture and monitoring. The integrated approach aims to broaden trial access for patients while streamlining sponsor and site responsibilities.
Roche Reports Phase III METEOROID Study Results for MOGAD
Roche announced that its subcutaneous antibody satralizumab, marketed as Enspryng, achieved a 68% reduction in relapse risk in the Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). At 48 weeks, 87% of patients on Enspryng remained relapse‑free versus...
Sanofi Reports the US FDA Approval of Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Children (≥1years)
Sanofi’s monoclonal antibody Tzield (teplizumab‑mzwv) received U.S. FDA approval under priority review to delay the onset of stage 3 type 1 diabetes (T1D) in children as young as one year who are diagnosed with stage 2 disease. The decision was driven by one‑year...
Lentinan‐Enhanced Mn3O4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment
Researchers have engineered a lentinan‑coated manganese oxide (Mn3O4@LNT) nanoparticle that can circulate long‑term and cross the blood‑brain barrier (BBB). Proteomic analysis revealed that the LNT coating reshapes the particle’s protein corona, enhancing BBB traversal and brain accumulation. In cellular and...
Roche’s Fenebrutinib Cuts Relapses in MS Amid Safety Concerns
Roche’s investigational BTK inhibitor fenebrutinib achieved 51.1% and 58.5% reductions in annualised relapse rates versus teriflunomide in the Phase III FENhance 1 and 2 trials for relapsing multiple sclerosis, while also cutting MRI lesion activity. The drug showed encouraging trends in disability‑progression measures...
Merck Reports the US FDA Approval of Idvynso for Virologically Suppressed HIV-1 Infection
Merck’s Idvynso, a once‑daily tablet combining 100 mg doravirine with 0.25 mg islatravir, received FDA approval as a switch regimen for virologically suppressed HIV‑1 adults. The approval rests on two Phase III trials—Trial 052 (n=513) and Trial 051 (n=551)—which demonstrated comparable viral suppression to existing...
Lupin Launches Generic Diabetes Drug in US After USFDA Approval
Indian pharma Lupin Ltd received FDA approval for its generic dapagliflozin‑metformin extended‑release tablets and launched them in the United States. The product matches the brand Xigduo XR in bioequivalence and is offered in four strength combinations. The launch adds a lower‑cost...
Two Drugs Stir Hope for Treatment of Deadly Pancreatic Cancer
Two experimental treatments presented at a San Diego cancer conference have shown early signs of efficacy against pancreatic cancer, a disease that kills more than 50,000 Americans each year. The data come from small, unpublished trials and the drugs have not...
SynbioTech's L. Plantarum FS4722 Emerges as a Potential Preventive Approach for Hyperuricemia
SynbioTech announced that its probiotic Lactiplantibacillus plantarum FS4722 markedly lowers serum uric acid in mouse models, matching the efficacy of conventional uric‑lowering drugs while showing no kidney toxicity. The strain works through a multi‑mechanism gut‑liver‑kidney axis: it reduces intestinal purine...
Multi-Regional Trials Have yet to Become the Norm
BioCentury’s website outlines a comprehensive cookie policy that categorises cookies into strictly necessary, functional, marketing, advertising, and analytics types. Strictly necessary cookies are always active and essential for authentication and site navigation, while functional cookies enable enhanced personalization. Marketing and...
Anti-Amyloid Drugs May Not Work Against Alzheimer's but if so, What Will?
A Cochrane systematic review of 17 clinical trials involving over 20,000 patients with early Alzheimer’s found that anti‑amyloid drugs produce little to no clinically meaningful improvement in cognition or daily function. The analysis also highlighted an increased risk of brain...
Natural GLP-1 Discovery Hidden in Joints Could Revolutionize Arthritis Treatment
A study published in The Lancet Rheumatology found trace amounts of the body’s natural GLP‑1 hormone in the synovial fluid of patients with rheumatoid arthritis and spondyloarthritis. Researchers compared joint‑fluid and blood samples from the INART biobank and observed a...
Noxopharm SOF-SKN Data Shows Prolonged Skin Retention with Minimal Systemic Absorption
Australian biotech Noxopharm announced preclinical pharmacokinetic results for its SOF‑SKN candidate, showing a skin half‑life of roughly 3.5 days with negligible systemic exposure. The active moiety, SOF‑16, demonstrated consistent dermal concentrations across normal and disease‑like skin and remained confined to...
#AAN26: Roche’s Multiple Sclerosis Pill Delays Relapse, but Liver Toxicity Could Need Monitoring
Roche’s experimental multiple sclerosis pill fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, more than doubled the relapse‑free interval compared with Sanofi’s oral therapy Aubagio in a late‑stage trial. The Phase 3 data showed roughly 68% of patients remained relapse‑free at...
STAT+: With Successful Trials, Roche Takes Its MS Drug to Regulators, but Safety Questions Loom
Roche presented data on its experimental multiple‑sclerosis drug fenebrutinib, which showed efficacy in three late‑stage trials by cutting relapse rates and slowing disability progression. The Swiss firm is now seeking regulatory approval, but analysts highlight liver‑safety signals and two drug‑related...
STAT+: From Revolution Medicines, More Strong Data on KRAS Drug and a Glimpse of a ‘Novel Class’ Beyond It
Revolution Medicines presented new clinical data on its next‑generation KRAS inhibitor daraxonrasib at the AACR meeting, highlighting strong first‑line activity and synergistic effects in combination regimens for advanced pancreatic cancer. The company also unveiled pre‑clinical results for RM‑055, a candidate...
STAT+: Kyverna Therapeutics Plans to Submit Cell Therapy for Stiff Person Syndrome for FDA Approval
Kyverna Therapeutics announced that its personalized CAR‑T cell therapy improved mobility and reduced disability in patients with stiff person syndrome, a rare autoimmune neurological disorder. The company plans to file an FDA submission by mid‑2026, which would make it the...
The Great Ozempic Experiment
GLP‑1 medications such as Ozempic and Zepbound have moved beyond weight‑loss to treat a spectrum of conditions, from traumatic brain injury to long Covid and addiction. An interactive New York Times report highlights that roughly one in eight Americans have tried these...
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks unveiled Phase 1 data for ZW191, a folate‑receptor‑α‑targeting antibody‑drug conjugate, at the AACR 2026 meeting. In platinum‑resistant ovarian cancer the drug showed a confirmed objective response rate of 61% at 6.4‑9.6 mg/kg, with a median progression‑free survival of 7.6 months and responses...
A Natural Protein May Protect the GI Tract From Infection
MIT researchers have identified the natural lectin protein intelectin‑2 as a dual‑action defender of the gastrointestinal tract. The protein binds galactose on bacterial membranes, trapping and destabilizing pathogens while also reinforcing the mucus barrier by attaching to mucins. Laboratory tests...
Medicare Indefinitely Delays Pilot Plan to Cover Weight Loss Drugs
Medicare’s Center for Medicare & Medicaid Services announced an indefinite postponement of its pilot program to cover prescription weight‑loss medications. The pilot, originally slated to test coverage for drugs such as Wegovy and Zepbound, was halted after participating insurers raised...
AI Tool Predicts How New Drug Molecules Move Before Costly Lab Tests
University of Oregon researchers unveiled an AI‑driven simulation tool that predicts how novel drug molecules move and bind inside the body, using only their chemical structure. By integrating physics‑based energy data with machine‑learning sampling, the model delivers coarse‑grained motion pathways...
STAT+: Insurers Refuse to Join Medicare Pilot Offering Weight Loss Drugs to Seniors at Steep Discount
The Trump administration negotiated a $245‑per‑month price with Eli Lilly and Novo Nordisk for obesity drugs, intending to offer seniors a $50 monthly copay through a Medicare pilot called BALANCE. Insurers refused to join, arguing the program would strain their finances. Consequently,...
Trump's Order Is a Milestone for Proponents of Using Psychedelics as Medicine
President Trump signed an executive order that mandates federal agencies to speed up research and regulatory approval of psychedelic compounds for mental‑health treatment. The order calls for the DEA to reassess scheduling of substances such as psilocybin and MDMA and...
Radiopharmaceutical Manufacturer Secures $30M to Bolster Domestic Isotope Production
Ionetix Corporation, a Michigan‑based cyclotron and radiopharmaceutical firm, announced a $30 million private‑placement raise at $3 per share. The capital will fund expansion of domestic radioisotope production for PET imaging and alpha‑emitter therapies and boost R&D on its superconducting cyclotron platform....
AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model
Researchers at UT MD Anderson unveiled Path-IO, a deep‑learning pathomics model that predicts outcomes and immunotherapy response in metastatic non‑small cell lung cancer (NSCLC). The AI was trained on 797 patients and externally validated on 280 cases, consistently outperforming the...
The BioPharm Brief: AI, Immunology, and Regulatory Momentum
AstraZeneca announced consistent Phase III data showing its IL‑33 biologic cuts COPD exacerbations, reinforcing the cytokine as a therapeutic target. Boehringer Ingelheim disclosed a broadened AI program that will be embedded across early discovery and development stages to speed target identification. The...
1 Parkinson’s Drug Can Hinder the Gold-Standard Treatment
Researchers at Yale School of Medicine discovered that catechol‑O‑methyltransferase inhibitors (COMT‑Is), commonly added to levodopa therapy for Parkinson's disease, can unintentionally reshape the gut microbiome. The altered microbiome favors growth of Enterococcus faecalis, a bacterium that metabolizes levodopa before it...
RFK Jr. Says China Is 'Eating Our Lunch' In Biotech Advances
HHS Secretary Robert F. Kennedy Jr. warned Congress that China is outpacing the United States in biotech, citing faster new‑drug approvals and a surge in clinical‑trial starts. He highlighted that China approved more than 70 novel therapies in 2025, compared with roughly 45...
CMS’ Chris Klomp, Stephanie Carlton Talk Affordability, Prior Authorization, Drug Pricing
CMS Deputy Administrator Chris Klomp and Chief of Staff Stephanie Carlton outlined the agency’s recent policy agenda, emphasizing four pillars—fraud reduction, affordability, health‑initiative programs, and AI‑driven streamlining. They highlighted a voluntary agreement to overhaul prior‑authorization processes and a 2025 most‑favored‑nation drug‑pricing pledge...
Why Managing Potency and Degradation Are Crucial in ADC Cleaning Validation
At INTERPHEX 2026, Paul Lopolito of STERIS highlighted the unique cleaning‑validation challenges posed by antibody‑drug conjugates (ADCs). He explained that ADCs merge highly potent small‑molecule payloads with large‑molecule biologics, creating divergent degradation profiles that demand product‑specific, risk‑based cleaning strategies. Lopolito...
Merck's Welireg Combo Fails in First-Line Kidney Cancer
Merck reported that adding Welireg (lenvatinib) to Keytruda (pembrolizumab) did not improve outcomes for treatment‑naïve patients with advanced renal cell carcinoma. In the phase‑3 CLEAR trial, the combination failed to meet its primary progression‑free survival endpoint, showing a median of...
Merck’s Fast-Ascending Kidney Cancer Drug Hits a Setback
Merck announced that Welireg, combined with Keytruda and Lenvima, failed to meet primary endpoints in a Phase 3 first‑line clear‑cell renal cell carcinoma trial, missing both progression‑free and overall survival benefits. The setback curtails Merck’s plan to use Welireg to offset...
FDA Public Meeting on Increasing Access to Nonprescription Drugs - 04/23/2026
The FDA announced a public meeting on April 23, 2026 to discuss expanding access to nonprescription, or over‑the‑counter (OTC), drugs. The agency is soliciting comments through May 8, 2026, with an earlier deadline of Feb 2, 2026 to shape the agenda. Topics include identifying conditions that...
FDA Accepts BLA for Gazyva/Gazyvaro for Systemic Lupus Erythematosus
Roche has received FDA acceptance of its supplemental Biologics License Application for obinutuzumab (Gazyva/Gazyvaro) as a treatment for systemic lupus erythematosus, with a regulatory decision expected by December 2026. The approval request is backed by the Phase III ALLEGORY trial, which...
Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval - 05/09/2024
On May 9, 2024, the FDA’s Office of Generic Drugs hosted a webinar on the redesigned pre‑submission meetings under GDUFA III. The session outlined new scope, procedural updates, and illustrated a hypothetical case to help sponsors prepare effective meeting requests. Speakers...
Complex Generics News
The FDA’s Center for Drug Evaluation and Research is intensifying its focus on complex generic drugs, which feature intricate active ingredients, formulations, or delivery systems. Recent milestones include the July 2023 approval of the first generic Vivitrol injectable and the March 2026...
Rapamycin Might Blunt Exercise Response in Humans
A double‑blind, placebo‑controlled trial gave 40 sedentary adults aged 65‑85 a weekly 6 mg dose of rapamycin alongside a 13‑week home‑based exercise program. Participants receiving rapamycin showed smaller gains in chair‑stand performance and trended worse on six‑minute walk and grip strength,...
Top 15 Specialty Pharmacies of 2025: Report
The Drug Channels report shows the specialty pharmacy market remains tightly concentrated, with PBM‑affiliated chains capturing roughly two‑thirds of dispensing revenue in 2025. Specialty drug spending rose 9.6% to $293.4 billion, while accredited locations topped 1,900, a 3% year‑over‑year increase. Hospital‑owned...
'It's Just the Beginning' For Pancreatic Cancer's Long-Awaited Breakthrough
Revolution Medicines’ KRAS‑G12D inhibitor daraxonrasib has entered late‑stage trials as a potential first‑in‑class therapy for pancreatic cancer, a disease that still carries a five‑year survival rate below 12%. Early data show tumor shrinkage in roughly a third of heavily pre‑treated...
Carvykti Shows Promise Before Multiple Myeloma; Two Megarounds; AstraZeneca Wins Twice
Researchers at Dana‑Farber Cancer Institute reported that all 20 high‑risk smoldering multiple myeloma patients treated with Carvykti, Janssen's BCMA‑directed CAR‑T therapy, achieved disease clearance. The single‑infusion regimen produced complete responses without immediate relapse, and patients remained progression‑free at a median...
BioAge Says Early Data Suggest ‘Best-in-Class’ Potential for Inflammation Drug
BioAge Labs released Phase 1 data for the 60‑mg dose of its NLRP3 inhibitor BGE‑102, confirming tolerability and inflammation‑lowering activity similar to the earlier 120‑mg readout. The oral pill crosses the blood‑brain barrier, opening possibilities for cardiovascular, obesity, eye and central‑nervous‑system...
Early Myocarditis Onset After Immunotherapy May Predict Treatment-Related Fatality
A new analysis of WHO VigiBase data presented at the AACR 2026 meeting shows that immune checkpoint inhibitor (ICI)‑induced myocarditis occurring within the first month of therapy dramatically increases the risk of death. Patients who develop myocarditis early are 59%...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions, Phase I Trial Results Indicate
A Phase I trial presented at AACR 2026 showed that injecting low‑dose nivolumab directly into precancerous oral lesions produced an 85% clinical response rate, with lesions shrinking an average of 60% and 41% achieving histologic downgrading. Patients received 10 mg or 20 mg...
Combining Cannabis with Opioids Offers No Added Pain Relief for Knee Arthritis Patients, Study Concludes
Researchers conducted a double‑blind, placebo‑controlled trial with 21 knee‑osteoarthritis patients to evaluate whether dronabinol, a synthetic THC, enhances the analgesic effect of hydromorphone. The study found that neither drug alone, nor their combination, produced meaningful acute pain relief during laboratory...
Tortugas Takes Neuro Deep Dive with $106M to Develop Eisai, Hansoh Programs
Tortugas, a Massachusetts‑based biotech, launched with $106 million in seed and Series A funding, securing clinical assets from Japan’s Eisai and China’s Hansoh Pharmaceutical. The capital will support two mid‑stage, oral small‑molecule trials targeting CNS disorders such as schizophrenia, tinnitus, and focal...
NIMBLE Trial Shows Efficacy of Cemdisiran in gMG: Tuan Vu, MD
The phase 3 NIMBLE trial evaluated cemdisiran, an RNA‑interference therapy, in patients with generalized myasthenia gravis (gMG). Over 26 weeks, cemdisiran monotherapy and its combination with pozelimab both achieved statistically significant improvements on the MG‑ADL scale versus placebo, and met the key...
Boehringer Targets AI-Driven Advances in Disease Research
Boehringer Ingelheim announced a £150 million (US$203 million) AI and machine‑learning accelerator in King’s Cross, London, expanding its global computational R&D network. The new hub, part of the UK Knowledge Quarter, will focus on disease biology, target identification and predictive modeling to...
BioAge Reports Positive Phase 1 Data for BGE-102
BioAge Labs announced Phase 1 results for BGE‑102, an oral, brain‑penetrant NLRP3 inhibitor, showing up to 86% reductions in high‑sensitivity C‑reactive protein (hsCRP) in obese participants. A 60 mg once‑daily regimen over 21 days achieved biomarker improvements comparable to the previously tested...
![[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/efeb4e97504f7f1cdd947972b3a5f013.webp)
[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?
The past eight years have seen a rapid expansion of targeted therapies for generalized myasthenia gravis, including complement C5 inhibitors, neonatal Fc receptor antagonists, and the anti‑CD19 B‑cell‑depleting antibody inebilizumab. Clinical trials have demonstrated meaningful reductions in disease activity, prompting...